Letrozol Sandoz (Letrozole)

Letrozole selectively blocks the aromatase enzyme (CYP19A1), preventing the conversion of androgens into estrogens. By lowering circulating estrogen levels, it removes the hormonal stimulus that promotes the growth of estrogen‑dependent breast cancer cells.

The specific dose of Letrozol Sandoz is determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and treatment goals. In clinical practice, a common starting point is 2.5 mg taken orally once daily, but the exact regimen must be set by a qualified healthcare professional.

Letrozol Sandoz is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant. Effective contraception is required during treatment.

To place an order, submit an enquiry on the Letrozol Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Letrozol Sandoz (letrozole) is a third‑generation aromatase inhibitor, similar in potency to anastrozole and exemestane. Compared with anastrozole, letrozole generally provides slightly greater estrogen suppression, which may translate into marginally higher efficacy in some settings, while sharing a comparable safety profile. Choice of agent depends on physician judgment and patient tolerance.

Letrozol Sandoz tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

Letrozol Sandoz is administered orally. The tablet is swallowed whole with a glass of water, typically once daily, and may be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious adverse events include severe liver injury, increased risk of bone fractures due to estrogen depletion, pulmonary embolism, and potentially life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored regularly for liver function, bone health, and any signs of clotting or hypersensitivity.

Letrozol Sandoz should not be used by pregnant or breastfeeding women, premenopausal women, patients with known hypersensitivity to letrozole or any excipients, and those with severe hepatic impairment. Caution is also advised for individuals with a history of osteoporosis, thromboembolic disease, or uncontrolled cardiovascular conditions.